After 620 million: Fosun Pharma made a big push into the field of medical devices

The launch of the split medical device segment has enabled Fosun Pharma to have a better capital platform for its acquisition in the medical device sector. Fosun Pharma's latest announcement stated that Sisram Medical Ltd (hereinafter referred to as “Sisram”), a non-wholly-owned subsidiary of Fosun Pharma, plans to be listed on the main board of the Hong Kong Stock Exchange.

For Fosun Pharma, the significance of Sisram's listing is to “establish an independent direct financing platform and provide continuous financial support”. Fosun Pharma said that after the completion of Sisram's listing, it will further increase its mergers and acquisitions in the field of medical devices. However, Fosun Pharma's medical device business is mostly acquired, and its business capability remains to be tested.

6.2亿之后:复星医药大举进军医疗器械领域

Spin-off

Fosun Pharma has long had the idea of ​​splitting the medical device sector. According to the listing plan, the size of the Sisram stock will be no less than 25% of the total share capital, including the new Sisram shares issued by Sisram and the old shares that may be sold by existing shareholders of Sisram. In addition, the underwriters will be granted no more than 15% of the over-allotment option. After the listing, Sisram will continue to be a holding subsidiary of Fosun Pharma.

Fosun Pharma established Sisram in Israel in 2013. In May of the same year, Sisram acquired the Israeli company Alma Lasers and made the company a major asset and business.

Sisram and its holding subsidiary, Alma Lasers, specialize in the design, development, production and sale of energy source therapeutic systems (including laser, intense pulsed light, infrared, radio frequency, ultrasonic energy-based medical devices ) for medical aesthetics and minimally invasive treatment. use. In the acquisition of Alma, Fosun Pharma has said that Alma will be listed separately in the 54 months since its acquisition, that is, at the end of 2017.

According to the data, Fosun Pharma is mainly divided into four major sectors: pharmaceutical industry, pharmaceutical business, medical service, medical device and medical diagnosis.

6.2亿之后:复星医药大举进军医疗器械领域

Organic Rhodiola Rosea Extract

Organic Rhodiola Rosea extract is an extract from the root of Rhodiola Rosea. Organic Rhodiola Rosea Extract is a herb extract. It has a sweet smell and a bitter taste. The main ingredients are salidroside, aglycone tyrosol, and rosavin, which have the effects of enhancing immune function, protecting cardiovascular and cerebrovascular, anti-cancer, and anti-depressive effects.

As a professional manufacturer and supplier of Organic Rhodiola Rosea extract, our Rhodiola Rosea extract is produced, processed, and stored in strict accordance with EU and USDA organic standards. Our Organic Rhodiola Rosea extract is 100% traceable.

Our Rhodiola Rosea extracts are all extracted from wild-collected Rhodiola roots. Afterward, it is processed and stored in an organic environment. All these processes are fully traceable and verifiable.

Rhodiola Rosea Extract,Organic Rhodiola Rosea Extract,Rhodiola Rosea,Organic Rhodiola Rosea

Organicway (xi'an) Food Ingredients Inc. , https://www.organic-powders.com

Posted on